Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
The Healthy @Reader's Digest on MSN
12 Silent Signs of Skin Cancer You’re Probably Ignoring
Subtle signs of skin cancer you shouldn't ignore When the weather gets warmer and daylight hours longer, people are more likely to spend time outdoors in the sun. This also means there’s an increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback